Cgix investor presentation Oct 2014

Empowering Personalized Cancer Treatment
October 2014

2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 2
Forward-Looking Statement
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services or Gentris, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks related to integration of the acquisitions of Gentris and BioServe and the realization of the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended June 30, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

Focused On Personalizing Cancer Diagnosis and Treatment
Globally Through Genomics
 Develop & Commercialize Unique Targeted Panels For The
Comprehensive Assessment of Cancer
 Develop Compelling Collaborations With Leading Institutions To Support
Genomic Test Adoption, Validation & Health Economics
 Establish Sales, Marketing & Commercial Infrastructure In US & India
 Serve Both the Clinical and Biopharma Communities Leveraging A
Standardized Global Infrastructure
 Selectively Acquire Companies & Capabilities That Further Our Mission of
Impacting The Personalization of Cancer Diagnosis & Management

Molecular Diagnostics are Changing our Understanding of Cancer While Providing New Tools to Diagnose & Treat Patients
Our unique focus & approach supports the entire cancer care continuum
Personalize therapeutic plan and treatment options
DIAGNOSIS
PROGNOSIS
THERANOSIS
Assist in patient outcome and disease management
What drug(s) to give, how much, and when?
What are my survival prospects?
Do I have cancer and what type?
Use genomics to provide an accurate and definitive typing of the cancer
Proprietary Products Focused Oncology Lab Comprehensive Report
Integrated Molecular Diagnostic Testing Brings Benefits
Across the Entire Oncology Ecosystem

CGI’s Mission is to Personalize and Improve the Success Rate in Cancer Treatment
Integrating & Delivering Genomic Information About a Patient’s Cancer
Can Improve Care & Reduce Cost
Phenotypic & Physical Examination
Morphologic & Pathological Analysis
Large & Multiple Specimens Required
Significant Delays to Treatment
Traditional Approach
Biomarkers and Companion Diagnostics
Genomic Analysis & Proprietary Algorithms
Reduced Size and Number of Specimens
Improved Diagnoses & Treatment Plans
Our Approach: Personalized Medicine
Target For Tomorrow
25%
Situation Today
Source: Clinical Trends in Molecular Medicine, Vol. 7, Issue 5
100%
Success Rate
Target Success Rate

The Acquisitions of BioServe India and Gentris Corporation Provide Significant Market Upside & Improve CGI’s Competitive Position
•Growth potential in integrating our oncology- focused testing capabilities with Gentris’ high-value contracts.
•Expansion of Gentris’ capabilities and portfolio to include oncology-focused pharmacogenomics services.
•24,000 sq. foot lab space (CLIA/CAP/GLP) with NGS, genotyping, and gene expression test capabilities.
Gentris Corporation
[Closed 7/16/14]
•Access to high-growth Indian diagnostics market – projected to grow at 15-20% per annum for the next decade.
•Accelerates next-generation sequencing development and validation of targeted hot spot oncology panels.
•Cost-effective expansion of genomic analysis & informatics capabilities with state of-the-art 14,000 sq. foot lab.
BioServe India
[Closed 8/18/14]

Our Expansion is Crucial for our Global Positioning as an Industry Leader in Genomics Testing and Services
Clinical Services and R&D
82 Employees as of July 1st
CGI is positioned as leader in oncology-focused genomics and is enabled to deliver
complete solutions to the clinical and research communities.
Clinical & Research Services
Addition of 33 employees
Pharmacogenomics Services
Addition of 41 employees

Unique, Scalable and Multifaceted Business Model With A Focus On Providing A Complete Solution
Suite of Products and Services Provides Multiple Growth Drivers and Value to Multiple Parties: Clinical Community, Biopharma & Medtech
CLINICAL SERVICES
Differentiated and complete disease-focused solutions
Superior turnaround times
World-class expertise in genomics and cytogenetics
Serving community hospitals and labs through unique Expand Dx™ program
BIOPHARMA PARTNERSHIPS
Biomarker and companion diagnostic development
World-class genomics and bioinformatics
Drug-specific and cancer-specific assays
Comprehensive focus in hematologic & urogenital cancers
PROPRIETARY PRODUCTS
Proprietary molecular diagnostics & FISH probes
Clinically validated
IP-protected
Sold globally
Probe manufacturing leverages low-cost, high scale facility in India

Our Target Markets in Oncology Testing Comprise Over 615,000 New Lives Annually in the U.S.
Ability to Impact Over 615,000 New Lives Annually in the U.S.
Source: American Cancer Society
156,420
2014 Estimated New Cases
(U.S.)
Death Rate 35%
Hematological:
Lymphoma, Leukemia, M. Myeloma
371,610 2014 Estimated New Cases (U.S.)
Death Rate 16%
Urogenital:
Kidney, Bladder & Prostate
86,970
2014 Estimated New Cases
(U.S.)
Death Rate 31%
Gynecological:
Cervical, Endometrial & Ovarian
6 Products Launched in Target Segments Over $6Bn in Annual U.S. Spend on Lab Testing In These Categories

6 Proprietary Diagnostic Products Commercially Launched & In Market
Incidence
Indication
Hematologic Cancers
106,770
(Annual New Cases, Global)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
142,360
Diffuse Large B-Cell Lymphoma
62,300
Follicular Lymphoma
17,795
Mantle Cell Lymphoma
Urogenital Cancers
274,000
Kidney Cancer
HPV-Associated Cancers
(FHACT®)
1,750,000
(Annual New Cases, US)
HPV+ Low Grade Cervical Lesions
Over 2.3 Mn Combined Annual New Cases Globally

Product Pipeline
Research &
Discovery
Clinical
Development
Commercial Development
Launch &
Market Entry
Indication
Development Stage
Hematologic Cancers
Multiple Myeloma
Comprehensive Myeloid Panel
[NGS-based]
Comprehensive CLL Panel
[NGS-based]
UroGenital Cancers
Bladder Cancer
Comprehensive Renal Panel
[NGS-based]
Cervical Cancer
HPV-Associated Cancers
(FHACT®)
Head & Neck Cancer

Despite Improved Cancer Care, Case Numbers for Hematologic Cancers are Still Rising
Genomics-Based Tests like MatBA® are Critical and Improve the Management and Cost of Hematologic Cancers
Source: Genzyme & Nature
Source: National Cancer Institute, National Center for Health Statistics, SEER Dataset of Incidence & Mortality, FDA
1
2
5
12
89
100
80
60
30
2
Number of Years Ago
11.1
12.6
15.5
18.5
20.0
19.7
20.5
21.2
5.6
6.2
7.1
7.9
8.7
8.2
6.9
7.3
1975
1980
1985
1990
1995
2000
2005
2010
Incidence Rate
Survival Rate
Identified Leukemia & Lymphoma Subtypes
Incidence & Survival Rates for NHLs
(US Only, per 100,000)

MatBA®-CLL/SLL Improves Risk Stratification & Outcome Prediction
Validated in Collaboration w/ Dr. Kanti Rai & Dr. Nicholas Chiorazzi (NSLIJ); 2 Datasets, 322 specimens
Additional Validations being conducted w/ HUMC & Dana Farber; 2 Cohorts, 350+ specimens
█ Favorable
█ Intermediate
█ Unfavorable
█ Favorable/
Intermediate
(no distinction)
38% of cases in our study have a favorable prognosis falling under "watch & wait" approach.
8% of cases with unfavorable prognosis missed by FISH and caught using MatBA®-CLL/SLL.
Impact on therapy selection & clinical management of CLL patients.
Genomic Aberrations Reported
by FISH:
4
Genomic Aberrations Reported
by MatBA®-CLL/SLL:
20
85%
15%
FISH
23%
39%
38%
(Current Method)
(CGI Method)

MatBA® can Group Patients into Risk Groups & Prognostication Classes
MatBA®- CLL / SLL is a diagnostic tool and prognostic indicator for patient stratification and improved patient management
Being actively used in clinical care, in clinical trials and in validation programs with Dana Farber, MSKCC and HUMC
20 key genetic events/sites classify CLL patients as having the potential for Poor outcome = High risk Intermediate outcome = Intermediate risk Good outcome = Low risk Detection of specific genomic imbalance in CLL/SLL by MatBA®-CLL/SLL correlates patient risk with time to first treatment (TTFT) and shorter overall survival (OS)
Patients classified as high risk showed a shorter TTFT compared to those classified as low or intermediate risk
Patients classified as high risk had significantly shorter OS times than those classified as low or intermediate risk
Provides additional risk stratification between low and intermediate risk patients, not currently available in other tests
Time to First Treatment (TTFT)
Time (months)
Time (months)
Proportion Surviving
Proportion Treatment- Free
– GOOD (n=74)
– INTERMED (n=107)
– POOR (n=47)
– GOOD (n=74)
– INTERMED (n=107)
– POOR (n=47)
P = 0.090
P = 0.001
P < 0.001
P = 0.010
Overall Survival (OS)
Leukemia & Lymphoma – Houldsworth, et. al Sept. 18, 2013

UroGenRA®-Kidney Can Guide Management of Patients with Renal Masses and Appropriate Treatment Selection
Clinical Benefits Include Reduction in Number of Highly Invasive Procedures and Time to Treatment Initiation, and Better Informed Treatment Selection
Development of diagnostic algorithm
>600 RCC malignant subtypes (in-silico: SNP)
>100 malignant and benign renal neoplasms (in-house: aCGH & FISH) Retrospective in-house FFPE validation (n>190) CCF
100% diagnostic yield
97% diagnostic sensitivity to distinguish benign from malignant renal neoplasms
93% sensitivity to distinguish malignant RCC subtypes
C. Magi-Galluzzi and E. Klein (Cleveland Clinic) Prospective ongoing percutaneous core needle biopsy (n>50) MSKCC
Demonstrated ability to diagnose pathologically “unclassifiable” biopsies prior to surgical intervention
J. Coleman and J. Durack (MSKCC)
PROBLEM
Men and women with renal masses often undergo unnecessary nephrectomy for accurate diagnosis and experience delay in treatment
SOLUTION
UroGenRA® will detect genomic aberrations in a single assay permitting accurate diagnosis (benign vs malignant, and malignant subtype) guiding appropriate management and treatment strategies

FHACT® - A New Genomic Aid In The Screening & Management Of Cervical Cancer
FHACT® Provides Critical Information Which Reduces
Unnecessary and Costly Colposcopies
Cervical cancer effects nearly 500,000 women globally each year with nearly 80% in developing countries.
Today, all these women are referred for colposcopy.
Women with abnormal or unclear Pap smears
55 Million
Pap smears per year
3.5 Million
Pap smears come back as unclear/abnormal
2 Million
biopsies performed
12,000
cases of cervical cancer

FHACT® Provides Information for Developing Treatment Plans Potentially Reducing Healthcare Costs & Procedures
FHACT® is the Only 4 Color FISH Probe that can be Used for Cervical Cancer Screening
as Additional Testing Before Referral for Colposcopy
Global Validation Partners
Genomic Amplification by Disease Category
Source: P. Luhn, J. Houldsworth, et al., Gynecologic Oncology (2013)
5
10
19
20
0
20
40
60
80
ptrend = 0.01
6
9
9
20
0
20
40
60
80
ptrend = 0.02
6
9
7
12
0
20
40
60
80
ptrend = 0.03
3
8
12
12
0
20
40
60
ptrend = 0.001
<CIN2
& NLIM
(n=11)
<CIN2 & LSIL (n=20)
CIN2
&/or HSIL
(n=10)
CIN3+
(n=7)
<CIN2
& NLIM
(n=11)
<CIN2
& LSIL
(n=20)
CIN2
&/or HSIL
(n=10)
CIN3+
(n=7)
FHACT® detects irreversible changes in cervical cells caused by HPV.

IP Position and Detailed Global Strategy
Strong and growing portfolio in molecular-focused patents for disease identification and stratification
IP-based on unique algorithms across a broad group of chromosomal regions
Validation of specific clinical endpoints that are associated with particular disease outcomes or decisions
Filing and maintenance of trademark portfolio
Tool for Diagnosis and Prognosis of Mature B-Cell Neoplasms
US Issued Patent 8,580,713
Europe 10803548.6
India 6657/DELNP/2012
Canada 2,785,656
Methods of Analyzing Chromosomal Translocations Using Fluorescence In Situ Hybridization (FISH)
Canada 2,447,320
Panel for the Detection and Differentiation of Renal Cortical Neoplasms
US 14/078,726
Europe 08844570.5
Methods for Detecting Human Papilloma Virus-Associated Cancers
US 13/227,027
US 13/474,111
PCT/US2011/050681
Methods and Tools for the Diagnosis of Female Gynecological Cancers and Precancers
US 61/581,350

Large, Targeted Market Opportunities
Target Markets
Commercialization Strategy
Community Hospitals
Regional Cancer Centers
Oncologists and Pathologists
Continue to growing sales force that calls on hospitals and regional laboratories
Plan development of national footprint through Expand Dx™
Biotechnology Companies
Pharmaceutical Companies
Leverage clinical infrastructure and proprietary product portfolio for testing services that support clinical trials
Expand sales emphasis of Select One®
Emerging Markets
Enhance distributor base in select emerging economies
Partner with leading local cancer care providers and hospitals to provide probes, arrays and clinical services
Collaborate to create and validate microarrays and other proprietary products
Accelerate launch of large scale studies
Universities and Research Centers

Unique Service Offering Developed to Enable Community Hospitals to Improve Cancer Outcomes & Treat Patients Locally
Delivers better outcomes to community hospitals and laboratories
Enables community hospitals to bring “state-of-the-art” genomic testing to patients
Brings personalized medicine to the community hospital vs. just at academic and teaching hospitals
Allows community hospitals to keep patients and treat them locally
Improving care and quality is critical to maintaining reimbursement for community hospitals
$600,000 - $800,000 USD in Testing Opportunity on Average per Hospital
Expanding & Developing Cancer Care is a Top Priority for Hospital CEOs & CFOs
4,000 to 5,000 Community Hospitals & Laboratories in the U.S.
85% Of All U.S. Cancer Patients are Initially Diagnosed in Community Hospitals & Laboratories

Through Acquisition, Clinical Trial Services Show Strong Growth and Robust Pipeline
Gentris Provides Pharmacogenomic Clinical Trial Services to Several Large Pharma Companies Including Merck, Novartis, Otsuka, Eisai and Bristol-Myers Squibb
GROWTH IN CGI’s SELECT ONE® CONTRACTS ($000)
21%
55%
ONCOLOGY DRUGS ASSOCIATED WITH BIOMARKER(S)
$300
$2,700
$8,500
$18,000
2011
2012
2013
2014
Approximate value of contracts with biotech and pharma clients
2011
2016
Source: Company Analysis and Management Estimates

Over 6,800 Oncology Trials in the US Aligned with our Core Markets
Number of Open Clinical Trials (U.S.)
1,439
1,453
2,178
1,765
Lymphoma
Leukemia
Urogenital
HPV-Associated
Source: www.clinicaltrials.gov

Gilead is Currently Using a Comprehensive Panel of CGI Services & Proprietary Products in National & International Trials for Hematologic Cancers
The Gilead Relationship Exemplifies the Significant Upside Potential of
CGI’s Select One® Offering
Highlights
Comprehensive, biomarker-based patient profiling will help risk stratification and response monitoring
Improved patient profiling will result in improved trial efficacy for Gilead
Testing will occur across several methodologies, including flow cytometry, FISH, sequencing and mutation assays, and MatBA® microarrays
CGI provides biomarker driven insight regarding patient targeting and potential outcomes
Trials cover both national and international locations with all patient specimens being processed in Rutherford, New Jersey
CGIX Press Release: Cancer Genetics, Inc. Selected By Gilead Sciences, Inc. to Provide Clinical Trial Services for International Trials in Chronic Lymphocytic Leukemia

Roche Partnership Expanding Market Presence Internationally
“By expanding our relationship, we are strengthening our ability to provide patients the best service possible.” Alvaro Soto, Roche Servicios, Central America & Caribbean General Manager
Highlights
CGI provides genomic and biomarker testing services to 14 countries in Central America and the Caribbean.
CGI won a global RFP to help a strategic personalized medicine initiative for Roche Servicios (Latin America)
Roche sends all patient samples to the Rutherford facility where they are catalogued and processed
CGI interacts with both Roche and the hospital staff (pathologists, oncologists and nurses) and supports delivery of reports through an online HIPAA compliant portal
CGI and Roche expanded this relationship in 2013 and will begin developing workshops and training programs to drive adoption of biomarker-based cancer diagnostics throughout Central America and the Caribbean
CGI and Roche recently further expanded this relationship with an exclusive multi-year deal in which CGI will develop a center of excellence for lung cancer testing utilizing Roche’s FDA-Approved cobas® platform
CGIX Press Release: Cancer Genetics, Inc. selected by Roche Servicios S.A. to provide services for the diagnosis and personalization of oncology treatment CGIX Press Release: Cancer Genetics, Inc. expands relationship with Roche Servicios S.A.

AstraZeneca Partnership A Testament to the Growing Global Awareness of the Value of the CGI Brand
“We chose to partner with Cancer Genetics in this endeavor because of their experience in biomarker-based diagnostic testing and their commitment to delivering timely and accurate results to healthcare professionals and patients.” Rodrigo Fernandez, Country President of AstraZeneca CAMCAR, S.A.
Highlights
CGI will provide biomarker and molecular based testing services focused on select oncology categories and trials
Services include complex testing for diagnosis and prognosis of cancer patients in Central America and the Caribbean
CGI will work in close conjunction with AstraZeneca on exploring expansion opportunities into additional geographic territories, further oncology categories, and into select oncology trials
The partnership will concentrate on multiple cancer categories, with lung cancer being an initial area of focus
CGIX Press Release: Cancer Genetics, Inc. Announces Partnership with AstraZeneca to Provide Biomarker & Molecular Based Testing

Collaborations with Premier Cancer Research Institutions Leading Differentiated Research & Driving Product Adoption
Research Collaboration/ Licensing
Clinical
Services
Partnership
Highlights


Kidney Cancer, DLBCL, MCL & FL

Joint Venture Focused on Oncology & Next Generation Sequencing

Cervical Cancer

DLBCL


CLL


Cervical Cancer & DLBCL

Cervical Cancer

Kidney Cancer


DLBCL, Head & Neck Cancers


CLL

Mayo Clinic Joint Venture Investing in the Future – OncoSpire Genomics
The Value and Focus of Next Generation Sequencing is Moving from Platforms to Clinically Relevant, Disease-Specific Applications
Highlights
JV, based in Rochester, MN, will develop clinical diagnostic products and services on NGS platform(s) in areas of high clinical need
Three initial projects in key oncology categories selected by the SRC (Scientific Review Committee): Lung Cancer, Multiple Myeloma, Follicular Lymphoma
CGI commits up to $6 M over initial three year period (2013 to 2015-16 expected)
Mayo commits to “in-kind” services and support, use of facilities, NGS capabilities and access to biorepository
Joint Venture is exclusive in the project areas selected by CGI & Mayo
Important company update and analyst day held November 22, 2013
Next Generation Sequencing in Oncology

OncoSpire Genomics Projects are Unique and Have High Value
1.6 million
new cases
200,000
new cases
20,920
new cases
Informed
Discovery
Clinical Development
Commercial Development
Market Entry
(with partners)
Lung Cancer
Multiple Myeloma
Follicular Lymphoma
Selected Projects Have Significant Clinical Value & May Yield Multiple Focused Panels to Become the Standard of Care in NGS-Based Oncology Management

Strong History of Growth CGI Revenue & Clinical Volume Trends (2009 – 2013)
54% Full Year 2013 Revenue Growth
$1.67
$2.52
$3.02
$4.30
$6.61
2009
2010
2011
2012
2013
2,321
3,146
3,622
6,610
10,771
2009
2010
2011
2012
2013
Total Revenue ($Mn)
Clinical Volume (Tests Processed)

Strong History of Growth - Revenue & Clinical Volume Trends (Q2 Comparison 2012-2014)
$1,148
$1,832
$3,231
Q2, 2012
Q2, 2013
Q2, 2014
Total Revenue ($000)
1,623
3,204
2,664
Q2, 2012
Q2, 2013
Q2, 2014
Clinical Volume (Tests Processed)
Combined CGI & Gentris Revenue

Summary Statement of Operations (1st Half Comparison 2012-2014)
Income Statement Item
1H, 2012
1H, 2013
1H, 2014
Combined 1H, 2014*
Revenue
$1,983
$3,050
$2,942
$6,508
Gross Profit
74
701
149
1,781
Gross Margin (%)
3.7%
23.0%
5.1%
27.4%
Research & Development (R&D)
1,050
951
1,703
2,043
Sales & Marketing (S&M)
716
832
1,667
1,703
General & Administrative (G&A)
2,329
2,961
5,127
7,092
Operating Profit (Loss)
(4,021)
(4,043)
(8,348)
(9,056)
Net Income (Loss)
(2,933)
(6,782)
(6,673)
(7,417)
$ in thousands
* The “Combined 1H, 2014” results are the aggregation of first half 2014 of both Cancer Genetics, Inc. and Gentris Corporation. The amounts may not be indicative of future results.
Actual 06/30/14
All Cash*
$43,418
Stockholders’ Equity
40,463
$ in thousands * All cash included $6,000 restricted to collateralize a credit line
Balance Sheet Information

Consistent Focus on Gross Profit Improvements Additional Efforts Focused Operationally in US & India
Gross Profit Margin
Highlights of Initiatives
(52%)
(39%)
(3%)
9%
26%
(1,000)
(800)
(600)
(400)
(200)
0
200
400
600
800
2009
2010
2011
2012
2013
$ in Thousands
Decrease CGI Costs for Development & Services
Migrate DNA manufacture and NT Kits for CGI probes
Develop remove G-Band analysis capability
Develop remote FHACT® analysis capabilities
Move entire probe manufacturing & assembly

Multiple Customer Types Provide Diversified Revenue Mix With Covered Lives Already in Place
Selected Payors
Direct Bill Customer Types
Biotechs
Pharmas
Academic
Cancer Facilities
Community &
Regional Labs
72+ million covered lives through multiple payors:
18%
21%
58%
3%
Medicare
3rd Party Insurance
Companies,
Hospitals
& Care
Facilities
Payor Revenue Mix 1H, 2014
Reimbursement Based
Direct Bill / Pay Based
3rd Party Insurance
Medicare
1H, 2014
Probes
Companies, Hospitals
& Care Facilities

Experienced and Focused Management and Boards
Scientific Advisory Board
Andrea Califano, Ph.D.
Chairman of the Columbia Initiative for Systems Biology
Associate Director for Bioinformatics, Herbert Irving Comprehensive Cancer Ctr
Timothy A. Chan, M.D., Ph.D.
Principal Investigator, Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center
Riccardo Dalla-Favera, M.D.
Director, Institute for Cancer Genetics at Columbia University
Vundavalli V. Murty, Ph.D.
Director, Cancer Cytogenetic Laboratory and Molecular Pathology at Columbia University
Hans-Guido Wendel, M.D.
Principal Investigator, Cancer Genetics Laboratory at Memorial Sloan-Kettering Cancer Center
Howard McLeod, PharmD
Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center
Andrew D. Zelenetz, M.D., Ph.D.
Chief of Lymphoma Service and Head of Molecular Hemo-Oncology Laboratory, Department of Medicine at MSKCC
Raju Chaganti, Ph.D., FACMG Founder
•35+ years in cancer research; 38 at MSKCC
•Major discoveries in cancer genomics
•Published 350+ articles, 4 patents
Panna Sharma President & CEO
•15+ years as advisor to global life science & healthcare cos.
•Founded TSG Partners
•Chief Strategy Officer, iXL (IIXL)
Edward J. Sitar Chief Financial Officer & Treasurer
•30+ yrs in finance & deal making in the healthcare industry
•Healthagen, ActiveHealth Management, Cadent Holding, MIM Corporation (Bioscrip), Vital Signs, Zenith/Goldline Pharmaceutical, Coopers & Lybrand
Jane Houldsworth, Ph.D. Vice President of R&D
•25+ years in translational oncology research
•Published 50+ articles, 4 patents
•NIH grantee
Chairman of the Board,
|
Keith Brownlie, CPA
|
Edmund Cannon
|
Raju Chaganti, Ph.D.
John Pappajohn
|
Franklyn Prendergast, M.D., Ph.D.
|
Paul Rothman, M.D.
|
Panna Sharma
Board of Directors
Officers & Management Team

Consistent Achievement of Milestones Expected in Coming Quarters
Increasing covered lives market access through additional payers & health care organizations
Launching multi-marker NGS panel for lymphoid malignancies
Additional international agreements with life science tools companies for DNA Probes and product distribution in key geographies
MatBA® – Next phase of data and results from Dana Farber and HUMC studies to help support value and reimbursement
Pursuing CE approval for IVDD use of FHACT® in E.U.
Additional news on biopharma partners & relationships
Pursuing additional indications for UroGenRA®-Kidney microarray
Close of BioServe transaction (Q3, 2014)
Migrated DNA-FISH Probe Manufacturing to India reducing cost, increasing capacity and improving operational flexibility
Launched UroGenRA®-Kidney, a unique microarray for kidney cancer diagnosis in collaboration with MSKCC
Collaborative Study of UroGenRA®-Kidney with Cleveland Clinic demonstrated 93% diagnostic accuracy – announced results at the AACR 105th Annual Meeting
Launched FHACT® outside the U.S. in collaboration with the National Cancer Institute research publication and in the U.S. as an LDT under CLIA
Promoted FHACT® at the ACOG Annual Meeting
Received CLIA Approval for MatBA®-MCL (Mantle Cell Lymphoma)
Finalized Agreement with Multiplan and Three Rivers which gave us access to 72+ million covered lives
Launched OncoSpire Genomics – A Next Generation Sequencing Joint Venture with Mayo Clinic and announced initial set of projects (lung cancer, multiple myeloma & follicular lymphoma)
Launched CALR Mutation Test – for the diagnosis of myeloproliferative neoplasms potentially evolving into acute leukemia
Announced Multi-Year PathAdvantage Collaboration – for FHACT® (cervical cancer)
Partnered with AstraZeneca – CGI will provide biomarker-based Dx in Central America and the Caribbean
Acquisition of Gentris Corporation – closed on July 16, 2014
Recent
Accomplishments
Upcoming Milestones and Value Drivers

For further information, please contact us at ir@cgix.com
Cancer Genetics, Inc.
Meadows Office Complex
201 Route 17 North
Rutherford, NJ 07070
(201) 528-9200
www.cancergenetics.com
100214

Cgix investor presentation Oct 2014

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Ähnlich wie Cgix investor presentation Oct 2014

Ähnlich wie Cgix investor presentation Oct 2014 (20)

Mehr von RedChip Companies, Inc.

Mehr von RedChip Companies, Inc. (20)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

Cgix investor presentation Oct 2014